Prusogliptin (DBPR108) is an experimental compound that functions as a dipeptidyl peptidase-IV inhibitor. It is being investigated as a pharmaceutical raw material for the management of type 2 diabetes.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1186426-66-3
Lumateperone tosylate
pharmaceutical raw material
Baricitinib
pharmaceutical raw material
Phosphoric acid--{1-(ethanesulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile (1/1)
pharmaceutical raw material
Modafinil sulfone
pharmaceutical raw material
(2S,4S)-4-fluoro-1-[2-[(2-methyl-4-oxo-4-pyrrolidin-1-ylbutan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile
VQKSCYBKUIDZEI-STQMWFEESA-N
CC(C)(CC(=O)N1CCCC1)NCC(=O)N2C[C@H](C[C@H]2C#N)F